Although clinical trials show encouraging results, challenges such as variability in histological outcomes, limited long-term data, and high costs persist
Although this evidence is currently based on animal studies, it is hoped that these findings can be replicated in humans
20-22 Although a reduction in the progression to end-stage kidney disease is yet to be definitively demonstrated, evidence for this class of medication having cardio-kidney protective effects in people with type 2 diabetes is accumulating
Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans
Whats the best way to take them for maximum absorption
Studies on insulinotrophic and anorexigenic effects of GLP-1 only recently have led to the development of a new class of drugs, often referred to as incretin drugs, which act as GLP-1 receptor agonists (GLP-1RAs) and are currently implemented in therapy for T2DM [13]
